BackAltimmune Overview

Altimmune Long Term Debt

Latest long-term debt for ALT: $36M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$35.58M

Peer average

Loading

Altimmune Long Term Debt History

Loading

Altimmune vs. peers: Long Term Debt Comparison

Loading

Altimmune Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Altimmune (ALT) FAQ

As of the most recent data (March 2026), ALT shows a long-term debt of $36M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALT's long-term debt is now $36M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Altimmune is outperforming or lagging.

Tracking ALT's long-term debt over time shows whether Altimmune is scaling, shrinking, or reshaping that part of the business. The current reading is $36M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Altimmune's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $36M) with ownership activity and broader fundamentals.

Altimmune's long-term debt is $36M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.